Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial
Vinai Gondi(Thomas Jefferson University Hospital), Minesh P. Mehta(Columbia University), Glenn Bauman(Thomas Jefferson University Hospital), Wolfgang A. Tomé(Albert Einstein College of Medicine), Jeffrey Greenspoon(Thomas Jefferson University Hospital), Wenyin Shi(Thomas Jefferson University Hospital), B. Corn(Thomas Jefferson University Hospital), Andrew A. Kanner(Thomas Jefferson University Hospital), Vijayananda Kundapur(Thomas Jefferson University Hospital), Lisa A. Kachnic(NewYork–Presbyterian Hospital), Howard A. Rowley(University of Wisconsin–Madison), Chip Caine(Thomas Jefferson University Hospital), Albert S. DeNittis(Thomas Jefferson University Hospital), Stephanie L. Pugh(American College of Radiology), André Konski(Hospital of the University of Pennsylvania), Sunjay Shah(Thomas Jefferson University Hospital), Merideth M Wendland(Thomas Jefferson University Hospital)
Cited by 1,133
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.2k